Enforcement Discretion Is Not Approval

On October 28, 2026, HHS filed a policy letting pharmacies compound six unapproved peptides without fear of FDA enforcement. The science didn't change. The enforcement posture did. That distinction is the whole story.

Policy explainer · Last updated October 2026

01What actually happened on October 28

The notice's own rationale, quoted from the public-inspection text: "HHS believes that there is significant interest in the use of these peptides in compounding given the lack of availability of approved products. Therefore, to expand and improve patient access, HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A."

That sentence is doing a lot of work, so read it precisely. The justification is interest plus lack of approved alternatives — not new evidence of safety or effectiveness. The action is not taking enforcement action — not granting approval, not adding anything to the 503A Bulks List, not completing the rulemaking that would formally permit compounding. The policy describes itself as interim, in place only while that list is developed through rulemaking.

This is the payoff of a story this site has tracked all month: the "in review ≠ in effect" correction. As of this morning, the policy was still sitting in White House (OIRA) review. By the afternoon, it was filed. The correction format still applies — it just has a new second half: in effect as enforcement discretion ≠ approved.

02The six peptides, and the one left out

The six covered peptides, with their evidence labels as this site has tracked them:

• BPC-157 — ANIMAL/PRECLINICAL. No human efficacy or safety trials established; the best-known human data remains anecdote and small, uncontrolled reports.
• TB-500 (thymosin beta-4 fragment) — ANIMAL/PRECLINICAL. Wound-healing and repair signals come from animal models, not human trials.
• KPV — PRECLINICAL. Anti-inflammatory mechanism work; no human efficacy trials.
• MOTS-c — ANIMAL/PRECLINICAL. Zero completed human trials; one Phase 2a prediabetes study has been recruiting with no results published.
• Semax — HUMAN-LIMITED. A registered medicine in Russia; no English-language cognition RCTs found.
• Epitalon — HUMAN-LIMITED. Small, older human studies, mostly in elderly populations; no modern registrational trial.

Notice what is not on the list: retatrutide, tirzepatide, semaglutide, and every other incretin. This policy covers six specific bulk substances. It is not a general peptide amnesty, and it changes nothing about the GLP-1 compounding fights that ended when the shortage declarations ended.

03What enforcement discretion means — and doesn't

Enforcement discretion is a decision not to act, not a decision that something is safe, effective, or legal. Three distinctions carry the whole story:

1. Not approval

HHS's own spokeswoman: the policy "does not grant FDA approval or establish clinical safety and effectiveness." None of the six is an FDA-approved drug, and no compounded medicine made from them is FDA-approved either. A pharmacy-compounded peptide and an approved drug are different legal objects, and this policy does not convert one into the other.

2. Not a final rule

The notice calls itself a draft. It says it does not create rights and is not binding on the department or the public. HHS may revisit it, in whole or in part, if a safety signal or a product-quality problem appears. A policy that can be narrowed or withdrawn on a safety signal is a conditional pause, not a settlement.

3. Not a general sale

The discretion covers compounding by a state-licensed pharmacy, a federal facility, or a licensed physician, for a patient-specific prescription, under conditions on ingredient quality, manufacturing standards, safety reporting, and labeling. It does not legalize the gray market: research-use-only vials sold online, without a prescription, from foreign manufacturers, remain exactly what they were yesterday — unapproved products outside any regulated channel. The policy's stated purpose is to discourage that market by offering a regulated lane, not to bless it.

04How we got here: the 2026 timeline

• September 2023 — FDA placed roughly 20 peptide bulk substances into interim 503A Category 2, citing significant safety concerns. Category 2 substances sat outside the Category 1 enforcement-discretion policy: not freely compoundable.
• February 27, 2026 — HHS Secretary Kennedy publicly announced intent to loosen restrictions on several peptides. A cabinet statement is not a rule; it changed no peptide's legal status on its own.
• April 2026 — FDA removed 12 peptides from Category 2 after their nominations were withdrawn. That administrative change removed the safety-concern designation — it did not move them to Category 1 or make them compoundable. Category 2 removal and 503A Bulks List inclusion are two separate regulatory actions.
• July 23–24, 2026 — The Pharmacy Compounding Advisory Committee (PCAC) recommended six of seven peptides for the 503A Bulks List. FDA's own scientists had recommended against all seven. The committee voted contrary to staff recommendations on all six favorable votes.
• October 14, 2026 — HHS/FDA sent the interim access policy to the White House (OIRA) for review. Text unpublished, peptide list unnamed.
• October 21–26, 2026 — The opposition organized: the Partnership for Safe Medicines petitioned FDA to block compounding of all seven and to set aside the July vote on conflict-of-interest grounds; a JAMA Viewpoint (Samantaroy, Xu, Lurie) argued the policy would destroy trial incentives; Doctors for America urged the White House to reject it.
• October 28, 2026 — The policy was filed: enforcement discretion for six peptides, publication October 30, two-week comment window.

The through-line: every step of this story has been a fight about which question the policy answers. The access camp asked where these compounds can be sold. The safety camp asked whether they work. This policy answers the first question, conditionally — and leaves the second exactly where it was.

05The opposition filed its brief too

The policy did not arrive into a vacuum. In the week before it was filed, the opposition built its record:

• JAMA Viewpoint (October 26) — Samantaroy, Xu, and Lurie argued the danger isn't any single peptide: it's that letting compounders sell unapproved peptides removes the incentive to ever run a trial. "Authorizing these peptides would create a huge, largely unregulated market that will be characterized by misleading claims, needless risk, and widespread grift." The argument is about trial incentives, not peptide efficacy — and it's the strongest version of the case against the policy.
• Partnership for Safe Medicines petition (October 21) — asked FDA to block compounding of all seven July peptides and to set aside the July advisory vote, alleging the committee was seated in violation of federal ethics and conflict-of-interest law, with members holding peptide-industry financial ties. The allegation is unadjudicated.
• The FDA scientists' own record — the July briefing said none of the seven had adequate characterization, meaningful human evidence, or sufficient safety data. That briefing is still the agency's scientific record, and this policy does not revise it.

06What this doesn't change

• The evidence labels don't move. BPC-157 is still animal/preclinical. MOTS-c still has zero completed human trials. Semax is still human-limited. An enforcement decision is not a data point.
• Gray-market vials are still gray-market. Research-use-only products sold online without a prescription are outside this policy entirely.
• The safety record is unchanged — and thin. The adverse-event record for these compounds is voluntary reports and anecdotes, not controlled safety data. A regulated compounding lane adds manufacturing standards; it does not retroactively generate a safety database.
• The international picture is unchanged. No regulator worldwide has approved these six for the uses they're marketed for. Saudi FDA and South Africa's SAHPRA issued warnings about unregistered peptides in the same week this policy was filed.
• The formal rulemaking is still pending. The 503A Bulks List decision — the actual, permanent answer to whether these peptides belong in compounding — has not been made. This policy is the bridge, not the destination.

07What to watch next

• October 30 — Federal Register publication; the two-week comment window opens (Docket HHS-OASH-2026-0496).
• The comment record — whether safety, quality, or conflict-of-interest arguments move the final policy, or whether it stands as filed.
• Safety signals — HHS reserved the right to revisit the policy on a safety signal or product-quality problem. The first serious signal under the new lane is the first real test of that reservation.
• The 503A Bulks List rulemaking — the permanent decision this interim policy is bridging toward.
• Whether the regulated lane actually shrinks the gray market — the policy's stated purpose. That claim is testable, and worth testing, rather than assuming.